Search results
19 sie 2023 · H. pylori infection is the most severe known risk factor for gastric cancer (GC), which is the second highest cause of cancer-related deaths globally. We conducted a systematic review and meta-analysis to assess the global prevalence of GC in H. pylori -infected individuals.
30 wrz 2024 · This community-based randomized clinical trial integrated H pylori stool antigen (HPSA) screening and treatment with fecal immunochemical testing (FIT) screening to determine whether an invitation to HPSA + FIT could reduce the incidence and mortality of gastric cancer compared with use of FIT alone. Methods.
20 kwi 2023 · Helicobacter pylori infection causes chronic gastritis, which can progress to severe gastroduodenal pathologies, including peptic ulcer, gastric cancer and gastric mucosa-associated lymphoid...
10 paź 2023 · In a prospective randomised, placebo-controlled study evaluating the effectiveness of H. pylori eradication in first-degree relatives of people with gastric cancer, from South Korea (New England Journal of Medicine), eradication was shown to significantly reduce the risk of cancer (by 45%) [24, 25]. The evidence for reductions in incidence and ...
29 maj 2024 · Helicobacter pylori treatment was associated with reduced gastric cancer risk for individuals with a high genetic risk during long-term follow-up but not for those with low genetic risk.
19 kwi 2023 · We show a progressive decline in the worldwide prevalence of infection, from 58·2% (95% CI 50·7–65·8) in 1980–90 to 43·1% (40·3–45·9) in 2011–22. This decline is particularly marked over the past decade and in regions with a high background prevalence of infection, such as the WHO African region.
3 mar 2020 · Helicobacter pylori (H. pylori) infection, the major cause of chronic gastritis, peptic ulcers and gastric cancer, infects approximately 50% of the world population, is also closely associated with many extra-gastrointestinal diseases.
